The Study to Reevaluate the Safety and Efficacy of Human Urinary Kallikrein
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 2186 participants.
Also called NCT02562183
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 2,186 participants
- Sponsor
- Techpool Bio-Pharma Co., Ltd.
- Registry
-
NCT02562183
-
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT02562183. Allocation not applicable; no masking; primary purpose treatment. Start 2015-08 (registry gives no type); primary completion 2018-11-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The Study to Reevaluate the Safety and Efficacy of Human Urinary Kallikrein
- Condition
- Cerebral Infarction
- Intervention (Drug)
- kallikrein
- Lead sponsor
- Techpool Bio-Pharma Co., Ltd.
Record details
- Record id
cardio:ct-nct02562183- Content hash
b18b530e4df452b6f0802be7f5427af0fe50e3babe2030f4f582f175e6eff3cf